E-series resolvins (RvE1, RvE2, RvE3) are Specialized pro-resolving mediators (SPMs) synthesized from EPA through two distinct enzymatic pathways: the aspirin-triggered COX-2 acetylation pathway in endothelial cells, and the lipoxygenase cascade in neutrophils and Th2 cells. They actively orchestrate resolution of inflammation by binding to ERV1/ChemR23 and other receptors to halt neutrophil recruitment, protect mucosal and bone tissue, and downregulate antigen presentation.
Think of inflammation as a warehouse fire where firefighters (neutrophils) keep arriving even after the flames are out, tracking water and debris everywhere, damaging the building further. E-series resolvins are the fire chief who shows up and does three critical things: First, they radio dispatch to stop sending more trucks (halt neutrophil recruitment). Second, they order the crews already there to pack up and leave (promote neutrophil apoptosis and efferocytosis). Third, they call in the repair contractors (protect epithelial barriers and bone tissue from collateral damage).
What makes RvEs unique is they can be "aspirin-triggered"—like having a backup chief who only shows up when aspirin acetylates COX-2. This is the body's dual-pathway insurance: even when the standard route (5-LOX/15-LOX in neutrophils) is overwhelmed, aspirin can flip COX-2 from making inflammatory prostaglandins to making resolution signals instead. The chief doesn't fight the fire—that's already done. The chief ends the emergency response so reconstruction can begin.
Synthesis Pathways:
-
Aspirin-Triggered Pathway (Endothelial):
- Aspirin irreversibly acetylates COX-2 at Ser-530
- Acetylated COX-2 converts EPA (C20:5 ω-3) → 18R-HEPE (instead of PGE3)
- 18R-HEPE released to neutrophils
- Neutrophil 5-LOX converts 18R-HEPE → 18R,5S-diHEPE → AT-RvE1 (aspirin-triggered RvE1)
-
Endogenous Pathway (Leukocyte):
- Neutrophil/Th2 5-LOX converts EPA → 5S-HEPE
- 15-LOX (or 12/15-LOX in Th2) converts 5S-HEPE → 5S,15S-diHEPE → RvE1
- Alternative 5-LOX products → RvE2, RvE3 via enzymatic rearrangements
Receptor Signaling:
- RvE1 binds ERV1/ChemR23 (Gαi-coupled GPCR) on monocytes, dendritic cells, NK cells
- ERV1 activation → ↓ cAMP → ↓ NF-κB nuclear translocation → ↓ IL-12, TNF-α
- Blocks CCL20 secretion → ↓ dendritic cell chemotaxis
- RvE1 also binds BLT1 (leukotriene B4 receptor) as partial agonist/antagonist
- Competitively inhibits LTB4-induced neutrophil chemotaxis
- Inhibits NF-κB activation in neutrophils
- Promotes neutrophil apoptosis via caspase-3 activation
Downstream Cellular Effects:
- Neutrophils: ↓ transmigration, ↓ TNF-α release, ↑ apoptosis, ↑ uptake by macrophages (efferocytosis)
- Macrophages: ↑ phagocytosis of apoptotic cells, ↓ pro-inflammatory cytokine production
- Dendritic cells: ↓ migration to lymph nodes, ↓ IL-12 production → attenuated Th1 priming
- Epithelial cells: ↑ tight junction protein expression (ZO-1, occludin), ↓ permeability
- Osteoclasts: ↓ RANKL-induced activation → ↓ bone resorption
- Microglia: ↓ IL-1β, IL-6, TNF-α production in CNS inflammation
graph TD
A["EPA C20:5 ω-3"] -->|Aspirin-acetylated COX-2| B[18R-HEPE]
A -->|5-LOX neutrophil| C[5S-HEPE]
B -->|5-LOX| D[AT-RvE1]
C -->|15-LOX| E[RvE1/RvE2/RvE3]
D --> F[ERV1/ChemR23 Receptor]
E --> F
E --> G[BLT1 Receptor]
F -->|"Gαi coupling"| H["↓ cAMP → ↓ NF-κB"]
H --> I["↓ IL-12, TNF-α, CCL20"]
G -->|Competitive antagonism| J[Block LTB4 signaling]
J --> K["↓ Neutrophil chemotaxis"]
J --> L["↑ Neutrophil apoptosis"]
I --> M["↓ DC migration"]
K --> N[Halt inflammatory infiltration]
L --> O[Enhanced efferocytosis]
Metabolic Inactivation:
- RvEs undergo rapid dehydrogenation by 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
- Oxidized metabolites lose receptor binding affinity
- Plasma half-life: 2-5 minutes (rapid clearance ensures tight temporal control)
Therapeutic Window:
E-series resolvins are relevant for conditions where inflammation has transitioned from acute to chronic, but resolution mechanisms are stalled—a hallmark of chronic low-grade inflammation and metaflammation.
Key Clinical Contexts:
-
Inflammatory Bowel Disease (IBD):
- RvE1 protects intestinal epithelium by upregulating tight junctions and reducing TNF-α-mediated barrier damage
- In Crohn's disease and ulcerative colitis, impaired SPM synthesis correlates with disease severity
- Intervention: Combine EPA supplementation (2-4g/day) with low-dose aspirin (75-150mg/day) to trigger AT-RvE pathway—particularly in patients on NSAIDs who may already have COX-2 acetylation
-
Periodontal Disease & Bone Health:
- RvE1 inhibits osteoclast activation via RANKL pathway suppression
- Protects alveolar bone in periodontitis—relevant for oral health interventions in 5 plus 2 Metamodel Protocol
- Also applicable to Osteoarthritis where subchondral bone inflammation drives cartilage loss
- Clinical marker: Salivary RvE1 levels inversely correlate with periodontal pocket depth
-
Autoimmune Conditions:
-
Neuroinflammation:
-
Aspirin-Triggered Enhancement:
- Low-dose aspirin + omega-3 = synergistic SPM production
- Mechanistic rationale for cardiovascular protection beyond antiplatelet effects
- Caution: Requires functional COX-2 expression; may be less effective in chronic NSAID users with COX-2 suppression
Evolutionary Mismatch Connection:
Modern omega-6:omega-3 ratios (15-20:1 vs ancestral 1-4:1) limit EPA substrate availability for RvE synthesis. This creates a "resolution deficit"—inflammation initiates normally but cannot self-terminate. The selfish immune system continues low-grade activation to compensate for poor resolution signaling, driving metabolic dysfunction (insulin resistance, hypothalamic inflammation).
Biomarker Integration:
- Omega-3 index <4% → insufficient EPA substrate
- AA:EPA ratio >15:1 → pro-inflammatory lipid mediator dominance
- High-sensitivity CRP >1 mg/L + normal WBC → suggests unresolved inflammation responsive to SPMs
- RvE1 binds ERV1/ChemR23 (Kd ~10 nM) and acts as BLT1 partial agonist at 10-100 nM concentrations
- Aspirin acetylates COX-2 at Ser-530, switching enzyme from PGE2 synthesis to 18R-HEPE production
- RvE1 reduces neutrophil transmigration by 40-70% in vitro and in vivo models at 10-100 ng doses
- Plasma half-life of RvEs: 2-5 minutes due to 15-PGDH-mediated dehydrogenation
- Salivary RvE1 concentrations: healthy ~10-50 pg/mL; periodontitis <5 pg/mL
- EPA supplementation (2-4g/day × 8-12 weeks) increases RvE biosynthetic capacity ~2-3 fold
- RvE1 reduces IL-12p70 production by dendritic cells by 50-80% at physiological concentrations
- Neutrophil apoptosis enhanced 2-4 fold by RvE1 exposure (24h cultures)
- Tight junction resistance (TEER) increased 30-60% in epithelial monolayers treated with RvE1
- Osteoclast differentiation (TRAP+ cells) reduced 40-60% in RANKL-stimulated cultures with RvE2/RvE3
- EPA — direct fatty acid precursor; substrate availability determines RvE biosynthetic capacity
- Specialized pro-resolving mediators (SPMs) — RvEs are one of four major SPM families alongside resolvins, protectins, maresins
- Resolvin D-series — complementary SPM family from DHA with overlapping but distinct receptor targets
- COX-2 — dual role: acetylated form produces RvE precursors; non-acetylated produces inflammatory prostaglandins
- aspirin — pharmacological trigger for AT-RvE pathway via COX-2 Ser-530 acetylation
- 5-LOX — key enzyme in both leukotriene synthesis (inflammatory) and RvE synthesis (resolving)
- 15-LOX — converts 5-LOX products to bioactive RvEs; high expression in Th2 cells and eosinophils
- neutrophils — both produce RvEs and are primary target for RvE-mediated recruitment inhibition
- Th2 — cells contributing to RvE synthesis via 12/15-LOX pathway
- endothelial cells — site of aspirin-triggered RvE synthesis; gate neutrophil extravasation
- inflammatory bowel disease — clinical context where RvE deficiency correlates with disease severity
- periodontitis — oral condition responsive to RvE-mediated bone protection
- Osteoarthritis — subchondral bone inflammation suppressible by RvEs
- microglia — CNS immune cells with cytokine production reduced by RvE1
- IL-12 — Th1-polarizing cytokine suppressed by RvE signaling through ERV1
- TNF-α — pro-inflammatory cytokine reduced by RvE-mediated NF-κB inhibition
- NF-κB — transcription factor downregulated by RvE signaling, key inflammatory pathway node
- efferocytosis — macrophage clearance of apoptotic neutrophils enhanced by RvEs
- LTB4 — neutrophil chemoattractant antagonized by RvE1 at BLT1 receptor
- tight junctions — epithelial barrier proteins upregulated by RvE1 (ZO-1, occludin)
- omega-3 fatty acids — dietary source of EPA substrate; omega-3 index predicts RvE biosynthetic potential
- chronic low-grade inflammation — pathological state characterized by resolution failure responsive to SPM therapy
- resolution of inflammation — active process coordinated by RvEs and other SPMs, not passive decay
- insulin resistance — metabolic consequence of unresolved inflammation; RvEs restore insulin signaling in adipocytes
- hypothalamic inflammation — central driver of metabolic dysfunction suppressible by RvE-mediated microglial deactivation